Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Cipro

Executive Summary

Ciprofloxacin approved Aug. 30 by FDA for the post-exposure prophylaxis of anthrax. As its Phase IV commitment Bayer will assist federal agencies in analyzing data in the event of an anthrax outbreak. Bayer is in discussions with the Centers for Disease Control & Prevention and the Department of Defense regarding Cipro stockpiling. The new indication will cover Cipro tablets, oral suspension and I.V. formulations

You may also be interested in...



Virtual Drug Development, Inc. Studying Pre-Exposure Antibiotic For Anthrax

Virtual Drug Development, Inc. is seeking to develop a pre-exposure prophylactic antibiotic for Bacillus anthracis that could serve as an alternative to the current anthrax vaccine.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel